Stocktoria
ARS Pharmaceuticals, Inc. SPRY
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-12-04
ARS Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30,000 | $1.3M | $5.5M | — |
| R&D expense | $13.2M | $19.6M | $20.3M | $18.4M | $20.3M | $24.6M |
| SG&A expense | $230.1M | $71.7M | $47.3M | $603,000 | — | — |
| Operating income | -$179.4M | -$3.1M | -$67.5M | -$35.5M | -$19.5M | -$32.9M |
| Income tax | -$80,000 | $288,000 | $0 | $0 | $0 | $0 |
| Net income | -$171.3M | $8.0M | -$54.4M | -$34.7M | -$20.2M | -$32.9M |
| EPS (diluted) | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-0.70 | — |
| Operating cash flow | -$170.9M | $13.5M | -$59.3M | -$40.1M | -$17.6M | -$31.2M |
| Free cash flow | -$171.2M | $13.0M | -$59.4M | -$40.3M | -$17.6M | -$32.1M |
| Cash & equivalents | $41.3M | $50.8M | $71.0M | $210.5M | $60.1M | $386.6M |
| Inventory | $31.4M | $10.5M | $0 | — | — | — |
| Total assets | $327.7M | $351.2M | $233.2M | $281.4M | $61.4M | $394.8M |
| Total liabilities | $213.4M | $94.4M | $2.4M | $8.5M | $16.7M | $11.9M |
| Shareholders' equity | $114.3M | $256.8M | $230.8M | $272.9M | -$31.3M | -$14.1M |
Growth · year-over-year · Revenue CAGR 97.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -5.5% | +297063.3% | -97.7% | -76.1% | — | — |
| Net income growth | -2241.8% | — | — | — | — | — |
| EPS growth | -2275.0% | — | — | — | — | — |
| Free cash flow growth | -1418.5% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.